Evaxion Biotech A/S Statistics
Share Statistics
Evaxion Biotech A/S has 5.41M shares outstanding. The number of shares has increased by 12.46% in one year.
| Shares Outstanding | 5.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 33.10M |
| Failed to Deliver (FTD) Shares | 15.50K |
| FTD / Avg. Volume | 4.65% |
Short Selling Information
The latest short interest is 121.06K, so 2.24% of the outstanding shares have been sold short.
| Short Interest | 121.06K |
| Short % of Shares Out | 2.24% |
| Short % of Float | 0.37% |
| Short Ratio (days to cover) | 1.64 |
Valuation Ratios
The PE ratio is -0.85 and the forward PE ratio is -1.89.
| PE Ratio | -0.85 |
| Forward PE | -1.89 |
| PS Ratio | 256.88 |
| Forward PS | 1.7 |
| PB Ratio | -3.97 |
| P/FCF Ratio | -1.05 |
| PEG Ratio | n/a |
Enterprise Valuation
Evaxion Biotech A/S has an Enterprise Value (EV) of 24.04M.
| EV / Earnings | -1.09 |
| EV / Sales | 329.3 |
| EV / EBITDA | -1.12 |
| EV / EBIT | -1.08 |
| EV / FCF | -1.35 |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of -1.83.
| Current Ratio | 1.18 |
| Quick Ratio | 1.18 |
| Debt / Equity | -1.83 |
| Total Debt / Capitalization | 220.67 |
| Cash Flow / Debt | -2.05 |
| Interest Coverage | -24.75 |
Financial Efficiency
Return on equity (ROE) is 4.68% and return on capital (ROIC) is -348.98%.
| Return on Equity (ROE) | 4.68% |
| Return on Assets (ROA) | -1.72% |
| Return on Capital (ROIC) | -348.98% |
| Revenue Per Employee | 1.49K |
| Profits Per Employee | -451.53K |
| Employee Count | 49 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -791.22K |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by -87.88% in the last 52 weeks. The beta is -0.23, so Evaxion Biotech A/S's price volatility has been lower than the market average.
| Beta | -0.23 |
| 52-Week Price Change | -87.88% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 2.87 |
| Relative Strength Index (RSI) | 35.27 |
| Average Volume (20 Days) | 333.19K |
Income Statement
In the last 12 months, Evaxion Biotech A/S had revenue of 73.00K and earned -22.13M in profits. Earnings per share was -8.11.
| Revenue | 73.00K |
| Gross Profit | 72.89K |
| Operating Income | -22.20M |
| Net Income | -22.13M |
| EBITDA | -21.40M |
| EBIT | -22.20M |
| Earnings Per Share (EPS) | -8.11 |
Balance Sheet
The company has 5.58M in cash and 10.87M in debt, giving a net cash position of -5.29M.
| Cash & Cash Equivalents | 5.58M |
| Total Debt | 10.87M |
| Net Cash | -5.29M |
| Retained Earnings | -107.97M |
| Total Assets | 15.19M |
| Working Capital | 0 |
Cash Flow
In the last 12 months, operating cash flow was -17.69M and capital expenditures -87.00K, giving a free cash flow of -17.78M.
| Operating Cash Flow | -17.69M |
| Capital Expenditures | -87.00K |
| Free Cash Flow | -17.78M |
| FCF Per Share | -6.5 |
Margins
Gross margin is 99.85%, with operating and profit margins of -30.41K% and -30.31K%.
| Gross Margin | 99.85% |
| Operating Margin | -30.41K% |
| Pretax Margin | -31.39K% |
| Profit Margin | -30.31K% |
| EBITDA Margin | -29.32K% |
| EBIT Margin | -30.41K% |
| FCF Margin | -24.35K% |
Dividends & Yields
EVAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -881.52% |
| FCF Yield | -35.71% |
Analyst Forecast
The average price target for EVAX is $11, which is 1095.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 1095.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 22, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -10.54 |
| Piotroski F-Score | 3 |